ASCO: The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma Date Published: View Poster: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS2068
